CREATE Medicines to Host Investor and Partnering Meetings at the 2026 Jefferies Global Healthcare Conference in London

Discussions will highlight progress from CREATE's four clinical-stage in vivo CAR programs across autoimmune disease and oncology

CAMBRIDGE, Mass., Nov. 6, 2026 — CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced that members of its senior management team will host one-on-one meetings with investors and prospective partners at the Jefferies Global Healthcare Conference in London, taking place from November 16–19, 2026, at the Waldorf Hilton and ME London. CREATE will be represented by Daniel Getts, PhD, CEO and Co-Founder, and Matthew Maurer, MD, Chief Medical Officer.

CREATE is a leader in in vivo CAR therapy, with over 80 patients treated, the largest clinical dataset in the field. The company's proprietary platform selectively programs immune cells directly inside the body for either transient or stable CAR expression, all from RNA. CREATE's clinical-stage programs include:

• CRT-402, a CD19-targeted in vivo CAR
• MT-303, a GPC3-targeted in vivo CAR
• MT-302, a TROP2-targeted in vivo CAR
• MT-304, a HER2-targeted in vivo CAR

Investors who wish to request a meeting should contact their Jefferies representative. Prospective partners may contact [email protected].

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
[email protected]

Investor Contact: 
Brian Korb
Astr Partners
[email protected]
+1 (917) 653-5122

SOURCE CREATE Medicines, Inc.